Could cause temporary or reversible harm; serious harm is unlikely.
cGMP deviations.
| Distributed by / for | Wells Pharma of Houston LLC |
| NDC | 73702-302-31 |
| Full product label | Ketamine Hydrochloride Injectable Solution, 50mg/ml, (50 mg per mL) Volume: 1 mL, 5265 Kitty Drive, Houston, TX 77054, NDC 73702-302-31. |
| Recalling firm | Wells Pharma of Houston LLC |
| Distribution | U.S. Nationwide. |
| Quantity | 4975 syringes |
| Recall initiated | 2026-04-01 |
| Report date | 2026-05-06 |
| Recall completed | — |
| Recall number | D-0507-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Houston TX United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗